Sandra and Edward Meyer Cancer Center

A representative image for this page.

Find a Cancer Clinical Trial

If you or a loved one were diagnosed with cancer or are at risk for cancer, your physician might suggest participating in a clinical research as a treatment option. By participating, you may gain access to new treatments or therapies that are not yet available to the public. We encourage you to volunteer for a study even if you are healthy. As a healthy volunteer, you play a vital role in developing new knowledge and contributing to cancer research.

Below are the studies open through the Meyer Cancer Center at our Manhattan, Queens, and Brooklyn hospitals.

Filter by Disease Category

A Phase 3 Randomized Study Comparing VRd Therapy followed by Ciltacabtagene Autoleucel, a CAR-T Therapy Directed Against BCMA vs VRd followed by Lenalidomide & Dexamethasone Therapy in Newly Diagnosed Multiple Myeloma for Whom HSTC is Not Planned

Diseases

Multiple Myeloma

Location(s):

Upper East Side - Manhattan

Primary Investigator(s)

Roger N Pearse, MD

A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations

Diseases

Acute Myeloid Leukemia

Location(s):

Upper East Side - Manhattan

Primary Investigator(s)

Alexander Ja-Ho Chou, MD

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Diseases

Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, B-cell Acute Lymphoblastic Leukemia, B-Lymphoblastic Leukemia

Location(s):

Upper East Side - Manhattan

Primary Investigator(s)

Lisa Giulino Roth, MD

A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Diseases

Ovarian/Peritoneal/Fallopian Tube Cancer

Location(s):

Upper East Side - Manhattan, Brooklyn, Queens

Primary Investigator(s)

Evelyn Cantillo, MD, MPH, Margaux Kanis, MD, David Fishman, MD

A Phase 3 Trial Investigating Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

Diseases

Leukemia, Acute Lymphoblastic Leukemia, B-Lymphoblastic Leukemia

Location(s):

Upper East Side - Manhattan

Primary Investigator(s)

Alexander Ja-Ho Chou, MD

A Phase 3, Open-Label, Randomized, 2 Part Study Comparing Gedatolisib in Combination with Palbociclib & Fulvestrant to SoC Therapies in Patients with HR+ HER2- Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor with Non-Steroidal AI Therapy

Diseases

Breast Cancer

Location(s):

Upper East Side - Manhattan

Primary Investigator(s)

Massimo Cristofanilli, MD

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma

Diseases

Esophageal Cancer

Location(s):

Upper East Side - Manhattan

Primary Investigator(s)

Manish A Shah, MD

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE- 010)

Diseases

Melanoma

Location(s):

Upper East Side - Manhattan

Primary Investigator(s)

Anna C. Pavlick, DO

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who

Diseases

Leukemia, Acute Myeloid Leukemia

Location(s):

Upper East Side - Manhattan

Primary Investigator(s)

Ellen K. Ritchie, MD

A Phase I, First-In-Human, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Diseases

Cancer, Colon and Colorectal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastrointestinal Cancer, Solid Tumors

Location(s):

Upper East Side - Manhattan

Primary Investigator(s)

Manish A Shah, MD